炎症因子在类风湿关节炎中的研究进展  

Research progress of inflammatory cytokines in rheumatoid arthritis

作　　者：罗帅 李小枫[1] 黄成[1] 温家根 李俊[1] LUO Shuai;LI Xiao-feng;HUANG Chen;WEN Jia-gen;LI Jun(School of Pharmacy, Anhui Medical University, Hefei 230032, China)

机构地区：[1]安徽医科大学药学院,安徽合肥230032

出　　处：《中国药理学通报》2022年第3期330-338,共9页Chinese Pharmacological Bulletin

基　　金：安徽省科技重大专项项目(No 008212929035)。

摘　　要：类风湿关节炎(rheumatoid arthritis,RA)是常见的自身免疫性疾病。在RA患者体内,血清或血浆细胞因子水平可能反映疾病的严重程度,细胞因子基因多态性可作为RA易感性和严重程度的标志。RA是一种全身性结缔组织疾病,不仅累及关节,而且其他器官(即肺、淋巴结、脾、皮肤、心脏或眼睛)也可能涉及。RA治疗的主要目标是通过尽可能早和强效的抗炎治疗来避免关节破坏。在过去的几十年里,当甲氨蝶呤无效或不耐受时,其它各种的疗法被用于改善患者关节和全身预后。其中,细胞因子靶向疗法被认定是最有前途的疗法之一。本文综述了不同炎症因子的效应功能和在RA发病中的作用,以及目前可用于治疗RA的以炎症因子为靶点的靶向抑制剂。Rheumatoid arthritis(RA)is the most common cause of autoimmune arthritis in the world.In RA patients serum or plasma cytokine levels may indicate the severity of the disease.Cytokine gene polymorphism can be used as a marker of RA susceptibility and severity.Rheumatoid arthritis is a systemic connective tissue disease.Not only joints,but other organs(lungs,lymph nodes,spleen,skin,heart or eyes)may also be involved.The main goal of treatment for rheumatoid arthritis is to avoid joint destruction through early and aggressive anti-inflammatory treatment.In the past few decades,various therapies were used for patients when methotrexate was ineffective or intolerant to alter the joint and systemic prognosis and the patients’disability.Among them,cytokine targeted therapy have long been identified to be the most promising therapy.This article reviews the effector functions of different inflammatory factors and their role in the RA pathogenesis and the targeted inhibitors targeting inflammatory factors that can currently be used for the treatment of RA.

关 键 词：类风湿关节炎 免疫疾病 免疫细胞 炎症因子 抗炎症因子药物 靶向抑制剂 

分 类 号：R364.5[医药卫生—病理学] R593.220.22[医药卫生—基础医学]